At Olympia Plaza Pharmacy, we are REMS-certified to accept Sublocade® prescriptions and administer the injection on-site. Sublocade is not dispensed directly to patients—it must be delivered to and administered by a certified healthcare professional under the SUBLOCADE REMS Program. We handle the logistics with prescribers and coordinate insurance, so patients can focus on recovery.
REMS-Certified Handling, End-to-End
We are certified under the SUBLOCADE REMS Program to order, receive, store, and administer Sublocade in a healthcare setting. The medication is never dispensed directly to a patient; we coordinate delivery for the scheduled appointment and administer in-clinic.
On-Site Injection by Licensed Clinicians
All injections are done by trained healthcare professionals in a private clinical setting, per labeling and REMS requirements.
Insurance & Prior Authorization (PA) Support
We verify benefits, manage prior authorization, and work with specialty distribution as needed to reduce delays. (In practice, access barriers and delays are common across California—our team minimizes that friction.)
Faster Start Options Are Available
In 2025, FDA-approved label updates added a rapid initiation pathway and alternative injection sites; our clinicians can determine whether this is appropriate on a case-by-case basis.
Tight Coordination With Care Teams
We collaborate with prescribers, counselors, and case managers to keep treatment consistent and on schedule.
Prescribers / Clinics: Seamless REMS-compliant fulfillment and administration partner for named-patient prescriptions.
Patients in Treatment: If your provider prescribes Sublocade, we provide the clinical setting, monitoring, and follow-through required by REMS.
Prescription Received (named-patient) →
Benefits & PA (we work with your plan) →
Schedule Injection (we coordinate shipment for the appointment) →
On-Site Administration (no take-home product) →
Ongoing Care & Refills.
No. Sublocade is not available in retail pharmacies; it’s only given by a certified healthcare provider under the SUBLOCADE REMS Program.
Per labeling, subcutaneous injection in the abdomen, thigh, buttock, or back of upper arm. Your clinician selects the site.
Labeling historically required prior stabilization on transmucosal buprenorphine; in Feb 2025, FDA approved rapid initiation options—your provider will decide the safest approach.
Coverage varies by plan. Many require benefit verification and PA; we do that for you and help navigate specialty distribution to avoid delays.